Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors

Published in Neuro Oncol, 2021

Recommended citation: A. Hagiwara, T. Oughourlian, N. Cho, J. Schlossman, C. Wang, J. Yao, C. Raymond, R. Everson, K. Patel, S. Mareninov, F. Rodriguez, N. Salamon, W. Pope, P. Nghiemphu, L. Liau, R. Prins, T. Cloughesy, B. Ellingson, "Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors." Neuro Oncol, 2021.